Last reviewed 2026-04-22 · How we verify

Sodium Aescinate

Sodium aescinate reduces vascular permeability and edema by stabilizing capillary endothelial cells and inhibiting inflammatory mediator release.

Sodium aescinate reduces vascular permeability and edema by stabilizing capillary endothelial cells and inhibiting inflammatory mediator release. Used for Cerebral edema (post-traumatic, post-operative, or ischemic stroke), Venous insufficiency and related edema.

At a glance

Mechanism of action

Aescin, the active component of horse chestnut seed extract, strengthens the blood-brain barrier and reduces fluid extravasation from capillaries. It inhibits hyaluronidase and other enzymes that degrade the capillary wall matrix, while also suppressing inflammatory cytokine production. This makes it effective for reducing cerebral edema and improving microcirculation.

Approved indications

• Cerebral edema (post-traumatic, post-operative, or ischemic stroke)
• Venous insufficiency and related edema

Common side effects

• Gastrointestinal disturbance
• Headache
• Dizziness
• Injection site reactions

Key clinical trials

• Sodium Aescinate for the Treatment of Low Back Pain (LBP) in Adults (PHASE1)
• Reducing Edema After intraCerebral Hemorrhage (PHASE4)
• Study on the Relationship Between Asymmetric Vascular Sign of Cortex and Prognosis in Massive Cerebral Infarction (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Sodium Aescinate CI brief — competitive landscape report
• Sodium Aescinate updates RSS · CI watch RSS
• Beijing Tiantan Hospital portfolio CI